Marstacimab

Modify Date: 2024-01-02 13:29:56

Marstacimab structure	Common Name	Marstacimab
	CAS Number	1985638-39-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Marstacimab

Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia[1][2].

Name	Marstacimab

Description	Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	Marstacimab (20，50 和 100 nmol/L) 降低血友病患者的全血样本中的玉米胰蛋白酶 (CT)[1]。 Marstacimab (16 μg/mL) 可缩短体外培养的人非血友病去血小板血浆样本的滞后时间并增加凝血酶生成[2]。 Marstacimab (16 μg/mL) 在体外可提高血友病 A 和血友病 B 血浆样本中凝血酶峰值[2]。
In Vivo	Marstacimab (0.5 mg/kg；静脉注射) 不影响小鼠急性出血模型的血流情况[2]。 Animal Model: Acute bleeding hemophilia A mouse models[2] Dosage: 0.5 mg/kg Administration: Intravenous injection, 0.5 mg/kg, once, before tail clip Result: Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
References	[1]. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806. [2]. Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6(2):e12679.

No Any Chemical & Physical Properties